Biohaven Acquires Rights For BHV-8000 From Hangzhou Highlightll Pharma - Quick Facts

Biohaven Ltd. (BHVN) has acquired global rights, excluding China regions, for the development of an oral, brain-penetrant, dual inhibitor of Tyrosine Kinase 2 and Janus Kinase 1 for the treatment of brain disorders. BHV-8000 was licensed from Hangzhou Highlightll Pharmaceutical Co. Ltd. Biohaven anticipates advancing the agent into a phase 1 study in 2023.

Highlightll will receive $10 million in upfront cash and $10 million in Biohaven equity, development and commercial milestone payments of up to $950 million, and tiered royalty payments ranging from mid-single digit to lower teens percentages. Biohaven and Highlightll will coordinate clinical development across global regions.

For More Such Health News, visit rttnews.com.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Domino's Pizza Inc., the largest pizza company in the world, is offering customers 50 percent off all menu-priced pizzas ordered online today through June 11 ahead of summer. The weeklong 50 percent off online deal is available on menu-priced pizzas ordered through Domino's online ordering channels. These include www.dominos.com, Domino's mobile app, Amazon Alexa, Google Home, Facebook Messenger.. J.T.M. Provisions Co. is recalling around 22,530 pounds of frozen, ready-to-eat beef chili with beans products distributed to schools, the U.S. Department of Agriculture's Food Safety and Inspection Service or FSIS announced. The recalled ietms may be contaminated with extraneous materials, specifically white plastic. Boeing and NASA announced further delay in the much expected launch of Starliner Crew Flight to the International Space Station following certain emerging issues with the capsule. Boeing has been developing its Starliner spacecraft after winning nearly $5 billion in contracts under NASA's Commercial Crew Program. Starliner's first crewed flight was earlier prepared for an April launch.
Follow RTT